Holen Sie sich die Stockscreener-App
3.03
38.36%
0.84
Handel nachbörslich:
2.98
-0.05
-1.65%
Schlusskurs vom Vortag:
$2.19
Offen:
$2.2
24-Stunden-Volumen:
6.04M
Relative Volume:
21.41
Marktkapitalisierung:
$428.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+61.17%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.10
$3.04
1-Wochen-Bereich:
$1.70
$3.04
52-Wochen-Spanne:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Firmenname
Veraxa Biotech Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare VRXA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
3.03 | 309.68M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag Aktie (VRXA) Neueste Nachrichten
VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire
Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - The Globe and Mail
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -
VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView
The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance
VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa
VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang
VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times
VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire
VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times
VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan
Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire
Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to book forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
VRXA|Veraxa Biotech AG Ord Shs|Price:2.320|Chg%:-0.03 - TradingKey
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VRXA: Veraxa Biotech AGInteractive Chart - Zacks Investment Research
Enterprise value to revenue forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Veraxa Biotech Holding AG (FRA:J8L0) Stock PDF (Updated: 2026/06/26) - GuruFocus
Cash per share of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
VERAXA Biotech (VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline - Yahoo Finance
Price to sales forward of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - USA Today
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026 - MEXC
VERAXA Biotech (VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - NewMediaWire
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development - Yahoo Finance
Veraxa Biotech expands Heidelberg lab space By Investing.com - Investing.com Australia
Finanzdaten der Veraxa Biotech Ag-Aktie (VRXA)
Es liegen keine Finanzdaten für Veraxa Biotech Ag (VRXA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):